STAT

SEPTEMBER 12, 2024

In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. The stock was trading 3.5% down in morning trading, after the company presented details on the trial with its once-daily pill CT-996 late on Wednesday.

Packaging 146

Packaging Diabetes Vaccines 146

European Pharmaceutical Review

AUGUST 21, 2023

Its diabetes treatment Mounjaro led this outcome. Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted.

Biosimilars 98

Biosimilars Diabetes Vaccines 98

Pharmaceutical Technology

MAY 16, 2023

increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2%

Diabetes 52

Diabetes Vaccines Drug Pricing 52